Eligible patients had clonal bone marrow plasma cells (BMPCs) ≥10%, plus at least one risk factor: serum M protein ≥30 g/L, IgA smoldering myeloma, immunoparesis with reduction of two ...

Serum levels of polyclonal IgG, IgA and IgM are usually decreased in patients with multiple myeloma (MM); however, little is known about the prognostic significance of polyclonal levels of IgE in ...

Background. A 59-year-old woman presented to the emergency department with a left rib fracture and was diagnosed with IgA multiple myeloma. The patient underwent autologous bone-marrow ...

Zigakibart is under clinical development by Novartis and currently in Phase III for IgA Nephropathy (Berger's Disease).

The patient‘s underlying disease was suspected to be the cause. As a consequence of multiple myeloma, his serum IgA concentration was 76.5 g/L (reference range: 0.7–5.0 g/L), and his total ...

Also, 44.6% of samples with IgG and IgA M-proteins had a normal κ/λ ratio. Of 357 sera that showed no M-protein by IFE, 95.8% exhibited a normal κ/λ ratio. Out of 11 patients with light chain ...